Reply
Marco Onofrj MD
Aging Research Center, Ce.S.I., “Gabriele d'Annunzio” University Foundation, University “Gabriele d'Annunzio,” Chieti-Pescara, Italy
Department of Neuroscience and Imaging, University “Gabriele d'Annunzio,” Chieti-Pescara, Italy
Search for more papers by this authorLaura Bonanni MD, PhD
Aging Research Center, Ce.S.I., “Gabriele d'Annunzio” University Foundation, University “Gabriele d'Annunzio,” Chieti-Pescara, Italy
Department of Neuroscience and Imaging, University “Gabriele d'Annunzio,” Chieti-Pescara, Italy
Search for more papers by this authorAngelo Di Iorio MD, PhD
Laboratory of Clinical Epidemiology, Geriatric Unit, Department of Medicine and Aging, University “Gabriele d'Annunzio,” Chieti-Pescara, Italy
Search for more papers by this authorAstrid Thomas MD, PhD
Aging Research Center, Ce.S.I., “Gabriele d'Annunzio” University Foundation, University “Gabriele d'Annunzio,” Chieti-Pescara, Italy
Department of Neuroscience and Imaging, University “Gabriele d'Annunzio,” Chieti-Pescara, Italy
Search for more papers by this authorMarco Onofrj MD
Aging Research Center, Ce.S.I., “Gabriele d'Annunzio” University Foundation, University “Gabriele d'Annunzio,” Chieti-Pescara, Italy
Department of Neuroscience and Imaging, University “Gabriele d'Annunzio,” Chieti-Pescara, Italy
Search for more papers by this authorLaura Bonanni MD, PhD
Aging Research Center, Ce.S.I., “Gabriele d'Annunzio” University Foundation, University “Gabriele d'Annunzio,” Chieti-Pescara, Italy
Department of Neuroscience and Imaging, University “Gabriele d'Annunzio,” Chieti-Pescara, Italy
Search for more papers by this authorAngelo Di Iorio MD, PhD
Laboratory of Clinical Epidemiology, Geriatric Unit, Department of Medicine and Aging, University “Gabriele d'Annunzio,” Chieti-Pescara, Italy
Search for more papers by this authorAstrid Thomas MD, PhD
Aging Research Center, Ce.S.I., “Gabriele d'Annunzio” University Foundation, University “Gabriele d'Annunzio,” Chieti-Pescara, Italy
Department of Neuroscience and Imaging, University “Gabriele d'Annunzio,” Chieti-Pescara, Italy
Search for more papers by this author
References
- 1 Thomas A, Bonanni L, Gambi F, Di Iorio A, Onofrj M. Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol 2010; 68: 400–404.
- 2 Weintraub D, Sohr, M, Siderowf A, etal. Amantadine use associated with impulse control disorders in Parkinson disease. Ann Neurol 2010; 68: 963–968.
- 3 Wang O, Kilpatrick RD, Critchlow CW, etal. Relationship between epoetin alfa dose and mortality: findings from a marginal structural model. Clin J Am Soc Nephrol 2010; 5: 182–188.
- 4 Fahn S. The history of dopamine and levodopa in the treatment of Parkinson's disease. Mov Disord 2008; 23: S497–S508.
- 5 Horstink M, Tolosa E, Bonuccelli U, etal.; European Federation of Neurological Societies; Movement Disorder Society-European Section. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease. Eur J Neurol 2006; 13: 1170–1185.
- 6 Horstink M, Tolosa E, Bonuccelli U, etal.; European Federation of Neurological Societies; Movement Disorder Society-European Section. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part II: late (complicated) Parkinson's disease. Eur J Neurol 2006; 13: 1186–1202.
- 7 Thomas A, Iacono D, Luciano AL, etal. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry. 2004; 75: 141–143.
Citing Literature
